Boston Scientific Corporation (NYSE:BSX) Shares Bought by Teacher Retirement System of Texas

Teacher Retirement System of Texas increased its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 25.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 871,649 shares of the medical equipment provider's stock after purchasing an additional 177,708 shares during the period. Teacher Retirement System of Texas owned 0.06% of Boston Scientific worth $87,932,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of BSX. Colonial Trust Co SC grew its holdings in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares during the period. Investment Management Corp VA ADV purchased a new stake in Boston Scientific in the 4th quarter valued at about $25,000. Sunbeam Capital Management LLC acquired a new position in Boston Scientific in the fourth quarter valued at about $26,000. Ameriflex Group Inc. purchased a new position in Boston Scientific during the fourth quarter worth about $31,000. Finally, Fairway Wealth LLC acquired a new stake in shares of Boston Scientific during the fourth quarter valued at about $36,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BSX has been the subject of a number of research analyst reports. Barclays increased their price objective on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Royal Bank Of Canada raised their price target on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Citigroup reaffirmed a "buy" rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Robert W. Baird increased their target price on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Finally, Truist Financial raised their target price on Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a report on Thursday, April 24th. Twenty-two research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $116.09.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the transaction, the chief executive officer directly owned 1,476,882 shares of the company's stock, valued at $153,137,894.58. This trade represents a 10.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president directly owned 36,193 shares of the company's stock, valued at approximately $3,441,592.37. This trade represents a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 461,970 shares of company stock valued at $47,755,193 over the last three months. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Up 0.6%

Shares of BSX stock traded up $0.67 on Friday, reaching $104.30. 2,931,148 shares of the stock were exchanged, compared to its average volume of 6,666,246. The company has a market capitalization of $154.30 billion, a price-to-earnings ratio of 76.13, a PEG ratio of 2.71 and a beta of 0.68. The business's 50 day moving average price is $103.42 and its 200 day moving average price is $100.22. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a twelve month low of $71.88 and a twelve month high of $107.53.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The business had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same period in the prior year, the firm posted $0.56 EPS. The business's quarterly revenue was up 20.9% compared to the same quarter last year. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.